Drug Digest: Advancing OSD: Continuous Production Considerations and Dose-Level Authentication

Published on: 

Pharmaceutical Technology editors interview oral solid dosage development experts from Syntegon and Colorcon, with discussions centered on continuous OSD production, containment safety, and authentication at the dose level.


In this exclusive Drug Digest video interview, Felicity Thomas and Feliza Mirasol, Pharmaceutical Technology editors, interview experts in solid dosage development and manufacturing. Alex Trombley, oral solid dosage (OSD) process specialist/business development manager of Syntegon, runs through the benefits of continuous OSD production and key considerations for containment and operator safety, while Ali Rajabi-Siahboomi, vice president and chief innovation officer, and Gary Pond, global lead, authentication, both of Colorcon, highlight the importance of authentication at the dose level.

Interviews featuring

Alex Trombley is Syntegon’s Business Development Manager where he is focused on technical support, customer trials, and market development for Huttlin products in North. Alex is experienced in early phase formulation development, process identification, scale-up, and technology transfer and has worked extensively with continuous manufacturing, high shear granulation, fluid bed granulation, tableting, and coating.

Ali Rajabi-Siahboomi, PhD, is the vice president and chief innovation officer at Colorcon, based at the Global Headquarter, USA. Rajabi-Siahboomi has held various academic positions in Nottingham and Liverpool JM Universities in the UK before joining Colorcon as technical director, responsible for Europe, the Middle East, and Africa in 2000. His main research interests are solid dosage form pharmaceutics, pharmaceutical technology with emphasis on oral drug delivery systems, solubility enhancement to improve bioavailbility, and consistency of drugs and bioequivalence formulations. He has published more than 300 articles, book chapters, abstracts, and patents and obtained his B.Pharm. and PhD in pharmacy from the University of Nottingham (UK).

Gary Pond is the global lead authentication for Colorcon and is responsible for leading the overall strategy, business planning, and operational execution for Colorcon’s on-dose authentication business. Pond has more than 25 years of experience in product management, marketing, operations, and digital transformation, and he is an established leader in on-dose authentication. Prior to Colorcon, Pond held marketing and operational leadership roles at Sanofi, Merck & Co, Abraxis Bioscience, and IQVIA.


This episode of Drug Digest is sponsored by:

  • Adare Pharma Solutions
  • Ascendia Pharmaceuticals
  • Coatings Place
  • JRS Pharma
  • Veltek Associates

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

  • November 2022: Automating pharma and biopharma processes